fulvic acid
Humic substances (HS) are relatively recalcitrant colored organic compounds naturally formed during long-term decomposition and transformation of biomass residues. The color of humic substances varies from bright yellow to light or dark brown leading to black. The term comes from humus, which in turn comes from the Latin word humus, meaning "soil, earth". Humic substances constitute the majority of organic matter in soil, peat, coal, and sediments, and are important components of dissolved natural organic matter (NOM) in lakes, rivers, and sea water. Humic substances account for 50 – 90% of cation exchange capacity in soils. — Wikipedia
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Earliest trial started May 1, 2010 (NCT01109381)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Unspecified targetCHELATING AGENT
chelating agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHumic substance ↗
- WikipediaLauric acid ↗
- WikipediaFulvic acid ↗
Also known as
- 1-undecanecarboxylic acid
- 1-undecanecarboxylic acid
- abl
- abl
- c12:0
- c12:0
- c12 fatty acid
- c12 fatty acid
- coconut oil fatty acids
- coconut oil fatty acids
- dao
- dao
- dodecanoate
- dodecanoate
- dodecanoic acid
- dodecanoic acid
- dodecanoic acid
- dodecanoic acid
- dodecanoic acid
- dodecanoic acid
- dodecoic acid
- dodecoic acid
- dodecylcarboxylate
- dodecylcarboxylate
- dodecylic acid
- dodecylic acid
- duodecyclic acid
- duodecyclic acid
- duodecylic acid
- duodecylic acid
- fluvic
- lauric acid
- lauric acid
- lauric acid
- lauric acid
- lauric acid
- lauric acid, ammonium salt
- lauric acid, barium and cadmium salt (4:1:1)
- lauric acid, calcium salt
- lauric acid, lithium salt
- lauric acid, magnesium salt
- lauric acid, nickel(2+) salt
- lauric acid, potassium salt
- lauric acid, sodium salt
- laurinsäure
- laurinsäure
- laurostearic acid
- laurostearic acid
- laurostearic acid
- n-dodecanoate
- n-dodecanoate
- n-dodecanoic acid
- n-dodecanoic acid
- potassium laurate
- sodium dodecanoate
- sodium laurate
- undecane-1-carboxylic acid
- undecane-1-carboxylic acid
- vulvic acid
- vulvic acid
- vulvic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04131335 | N/A | Oct 14, 2019 | University of London |
| NCT02592486 | Phase 4 | Nov 1, 2015 | Kameda Medical Center, Merck, Osaka University, PPD |
| NCT02982616 | N/A | Aug 1, 2015 | Katholieke Universiteit Leuven |
| NCT02984150 | N/A | Nov 1, 2014 | Katholieke Universiteit Leuven |
| NCT01109381 | Phase 1/Phase 2 (Phase 2) | May 1, 2010 | Singapore General Hospital, Synergy Pharmaceuticals |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Katholieke Universiteit Leuven | Academic/Hospital | 2 | 2 | 1 | 2014 |
| Kameda Medical Center | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Merck | For profit | 1 | 0 | 1 | 2015 |
| Osaka University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| PPD | For profit | 1 | 0 | 1 | 2015 |
| Singapore General Hospital | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Synergy Pharmaceuticals | For profit | 1 | 1 | 1 | 2010 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2019 |